Our research focuses on the development
and understanding of new organic reactions with particular emphasis on
using transition metal catalysis to create new chiral molecules. Once
developed, we then apply our new chemistry to the synthesis of
biologically active and medicinally important compounds. In
collaboration with biologists and clinical physicists we also test the
biological properties and study the potential applications of our new
compounds.
1. Development of Palladium-Catalysed
Aza-Claisen Rearrangements for the Synthesis of Natural Products: Early
studies on the use of the Overman rearrangement for the synthesis of (2
S,3
S,4
R)-γ-hydroxyisoleucine,
1
the amino acid component of the natural product, funebrine have led to
the development of a palladium(II)-catalysed, ether-directed
aza-Claisen rearrangement. Extensive experimentation has allowed the
identification of the methoxymethyl (MOM) ether as the most effective
at directing the metal catalyst to one face of the allylic
trichloroacetimidate resulting in a stereoselective rearrangement
giving the major erythro-product in ratios of up to 16:1.
2,3
Further studies have shown the involvement of both oxygen atoms of the
MOM-group in coordinating the catalyst and that other metals such as
Pt(II), Au(I) and Au(III) can also be used to catalyse the reaction.
4-6
We have shown that the products of this reaction, allylic
trichloroamides can be easily oxidised to give after deprotection, the
corresponding β-hydroxy-α-amino acid.
7 Alternatively, used
in conjunction with ring closing metathesis reactions has led to the
preparation of simple pyrrolidine and piperidine natural products such
as α-conhydrine.
3
We have also shown that linear allylic trichloracetimidates with a
side chain containing a terminal alkene can undergo a tandem, one-pot
aza-Claisen rearrangement/ring closing metathesis resulting in the
direct and highly efficient synthesis of cyclic allylic amides.
8
Using side chains of different lengths has allowed the preparation of
5-, 6-, 7- and 8-membered analogues in excellent yields and the use of
chiral Pd(II)-catalysts such as (
S)-COP-Cl
results in the asymmetric synthesis of these compounds. The products of
this highly efficient one-pot tandem process, cyclic allylic
trichloracetamides, are excellent synthetic intermediates and can be
easily manipulated to introduce a range of diverse functional groups.
These are currently being used for the total synthesis of piperidine
and amaryllidaceae alkaloids, such as (+)-γ-lycorane and
(+)-2-deoxylycoricidine.
1. A. G. Jamieson, A. Sutherland and C. L. Willis,
Org. Biomol. Chem., 2004,
2, 808.
2. A. G. Jamieson and A. Sutherland,
Org.
Biomol. Chem., 2005,
3,
735.
3. A. G. Jamieson and A. Sutherland,
Org.
Lett., 2007,
9,
1609.
4. A. G. Jamieson and A. Sutherland,
Tetrahedron,
2007,
63, 2123.
5. A. G. Jamieson and A. Sutherland,
Org.
Biomol. Chem., 2006,
4,
3889.
6. M. D. Swift and A. Sutherland,
Tetrahedron
Lett., 2007,
48,
3771.
7. K. N. Fanning, A. G. Jamieson and A. Sutherland,
Org. Biomol. Chem., 2005,
3, 3749.
8. M. D. Swift and A. Sutherland,
Org.
Lett., 2007,
9, 5239.
2.
New Tracer Agents For The SPECT
Imaging Of The Noradrenaline And Peripheral Benzodiazepine Receptors:
In collaboration with Dr Sally Pimlott (Western Infirmary) and Dr
Deborah Dewar (Dept. of Clinical Medicine), we have initiated a
programme for the development of radioiodinated compounds for the
Single Photon Emission Computerised Tomography (SPECT) imaging of
neurological receptors that are implicated in a range of neurological
disorders such as clinical depression, Parkinson’s disease, Alzheimer’s
disease, anxiety and stroke. For example, iodinated stereoisomers and
derivatives of reboxetine have been prepared for the SPECT imaging of
the noradrenaline receptor.
1,2 These compounds have been
prepared using the Sharpless asymmetric epoxidation to introduce the
stereogenic centres. Construction of the morpholine ring was then
followed by a copper catalysed aromatic halogen exchange reaction to
introduce the iodine label. In vitro testing of these compounds using a
[
3H]nisoxetine displacement assay with homogenised rat brain
show these compounds to have nanomolar affinity with the noradrenaline
receptor.
2
A short, flexible synthesis of PK11195, a potent ligand for the
peripheral benzodiazepine receptor has also been developed.
3
This new approach involves a Heck type reaction for the synthesis of
the isoquinoline ring, introduction of the chlorophenyl group using a
Suzuki reaction and finally formation of the side-chain amide using an
acylation/alkylation two-step strategy. The flexibility of this
approach has been demonstrated by the synthesis of a bromo-analogue
which has been used to prepare the corresponding iodide and an
organostannane for SPECT imaging.
4 Use of these derivatives
show that radioiodination is most efficient using an electrophilic
iododestannylation reaction giving radiolabeled [
123I]-PK11195
with excellent specific activity. Work is currently underway on the
design and synthesis of new structural analogues of PK11195 that may
lead to imaging agents with greater selectivity for the peripheral
benzodiazepine receptor.
1. N. K. Jobson, R. Spike, A. R. Crawford, D. Dewar, S. L. Pimlott and
A. Sutherland,
Org. Biomol. Chem.,
2008,
6, 2369.
2. N. K. Jobson, A. R. Crawford, D. Dewar, S. L. Pimlott and A.
Sutherland,
Bioorg. Med. Chem. Lett.,
2008,
18, 4940.
3. L. Stevenson, S. L. Pimlott and A. Sutherland,
Tetrahedron Lett., 2007,
48, 7137.
4. S. L. Pimlott, L. Stevenson, D. J. Wyper and A. Sutherland,
Nucl. Med. Biol., 2008,
35, 537.
3.
Synthesis and Design of Substituted
Polyazamacrocyles, New
Anti-Parasitic Agents: In collaboration with Dr Michael Barrett
(Division of Infection and Immunity), we have initiated a research
programme to develop new compounds to treat human African
trypanosomiasis and malaria. The aim in this programme was to develop
compounds which might interfere with polyamine biosynthesis in
parasites and thus, a number of novel polyazamacrocycles were developed
with reactive functional side-chains and shown to have significant in
vivo activity (e.g.
1).
1 More
recently work has begun to
probe the structure activity relationship of these compounds and it has
been found that these compounds are toxic to both trypanosomes and
malaria without the need for reactive side chains. Moreover, by
incorporating alkyl or aryl groups into the back bone of the macrocycle
has allowed the generation of a series of compounds which are more
stable and thus have more potential as anti-parasitic agents (e.g.
2).
2
Current work is now studying the functionalisation of these compounds
with moieties such as guanidine and benzamidine groups which are
recognised by specific parasite receptors (e.g.
3).
3 The aim is to
develop compounds that are not only potent but also parasite specific.
1. J. M. Wilson, F. Giordani, L. J. Farugia, M. P. Barrett, D. J.
Robins and A. Sutherland,
Org.
Biomol. Chem., 2007,
5,
3651.
2. C. M. Reid, C. Ebikeme, M. P. Barrett, E.-M. Patzewitz, S. Muller,
D. J. Robins and A. Sutherland,
Bioorg.
Med. Chem. Lett., 2008,
18,
2455.
3. C. M. Reid, C. Ebikeme, M. P. Barrett, E.-M. Patzewitz, S. Muller,
D. J. Robins and A. Sutherland,
Bioorg.
Med. Chem. Lett., 2008,
18,
5399.
4.
New Approaches for the Synthesis of
Amino Acids: We have a general interest in the novel and
efficient synthesis of amino acids of particular biological importance.
For example, a chiral pool approach from
L-aspartic
acid has been developed for the rapid synthesis of isotopically
labelled
L-arginine.
1 These types of
isotopically labelled amino acids have application in protein structure
determination and in elucidating natural product biosynthesis.
Similarly, a chiral pool approach from
L-aspartic acid
has been utilised for the preparation of (
S)-gizzerosine.
2 This
amino acid causes gizzard erosion and is a potent agonist of the
histamine H
2-receptor. Using a different strategy,
(+)-blastidic acid, the β-amino acid component of the
peptidyl-nucleoside antibiotic, (+)-blasticidin S has been prepared
using β-alanine as the starting material and an asymmetric conjugate
addition reaction to effect the key step.
3
1. D. J. Hamilton and A. Sutherland,
Tetrahedron
Lett., 2004,
45, 5739.
2. K. N. Fanning and A. Sutherland,
Tetrahedron
Lett., 2007,
48, 8479.
3. R. Bischoff, N. McDonald and A. Sutherland,
Tetrahedron Lett., 2005,
46, 7147.
Acknowledgements:
We are grateful to the following organisations for their
financial support
of our
work.